文献速递脊柱关节炎

比美吉珠单抗双中和IL-17A与IL-17F治疗银屑病关节炎:来自临床前实验和随机安慰剂对照临床试验的证据表明IL-17F参与人类慢性组织炎症

Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation.
PubMed 文献 · Ann Rheum Dis · 2017-12-23

该研究通过临床前实验和一项随机安慰剂对照概念验证试验,评估比美吉珠单抗(同时中和IL-17A和IL-17F)在银屑病关节炎中的作用。临床前实验显示IL-17F诱导与IL-17A相似的炎症反应,双中和比单独抑制更有效抑制细胞因子反应和中性粒细胞趋化。试验中,比美吉珠单抗组(n=39)在关节和皮肤疗效上优于安慰剂组(n=14),第8周ACR20达标率80.0% vs 16.7%,PASI100达标率86.7% vs 0%,持续至第20周,未出现意外安全性信号。

要点

  • 临床前实验显示IL-17F诱导与IL-17A相似的炎症反应,双中和比单独抑制更有效抑制体外细胞因子反应和中性粒细胞趋化。
  • 概念验证试验达到预设疗效成功标准,汇总前三个剂量组第8周ACR20达标率80.0% vs 安慰剂16.7%(后验概率>99%)。
  • 汇总前三个剂量组第8周PASI100达标率86.7% vs 安慰剂0%,疗效持续至第20周,未出现意外安全性信号。

核心结论

  • 数据支持IL-17F是人类慢性组织炎症的关键驱动因素,并为在银屑病关节炎及相关疾病中双中和IL-17A和IL-17F提供了依据。

研究设计与样本

  • 临床前实验使用疾病相关人类细胞评估IL-17A和IL-17F在组织炎症中的作用。
  • 一项安慰剂对照概念验证临床试验将银屑病关节炎患者随机分配至比美吉珠单抗组(n=39)或安慰剂组(n=14)。
  • 研究评估比美吉珠单抗(一种人源化单克隆IgG1抗体,中和IL-17A和IL-17F)多剂量(第0、3、6周给予240 mg/160 mg/160 mg;80 mg/40 mg/40 mg;160 mg/80 mg/80 mg和560 mg/320 mg/320 mg)的安全性、药代动力学和临床疗效。

主要发现

  • IL-17F在皮肤和关节细胞中诱导与IL-17A定性相似的炎症反应。
  • 比美吉珠单抗双中和IL-17A和IL-17F比单独抑制IL-17A或IL-17F更有效地抑制体外细胞因子反应和中性粒细胞趋化。
  • 概念验证试验达到两项预设疗效成功标准,并在关节和皮肤中显示快速、深度的应答(汇总前三个剂量组 vs 安慰剂第8周:ACR20达标率80.0% vs 16.7%(后验概率>99%);PASI100达标率86.7% vs 0%),持续至第20周,未出现意外安全性信号。

关键数值与推荐

  • 汇总前三个剂量组 vs 安慰剂第8周ACR20达标率80.0% vs 16.7%(后验概率>99%)。
  • 汇总前三个剂量组 vs 安慰剂第8周PASI100达标率86.7% vs 0%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Interleukin (IL)-17A has emerged as pivotal in driving tissue pathology in immune-mediated inflammatory diseases. The role of IL-17F, sharing 50% sequence homology and overlapping biological function, remains less clear. We hypothesised that IL-17F, together with IL-17A, contributes to chronic tissue inflammation, and that dual neutralisation may lead to more profound suppression of inflammation than inhibition of IL-17A alone. METHODS: Preclinical experiments assessed the role of IL-17A and IL-17F in tissue inflammation using disease-relevant human cells. A placebo-controlled proof-of-concept (PoC) clinical trial randomised patients with psoriatic arthritis (PsA) to bimekizumab (n=39) or placebo (n=14). Safety, pharmacokinetics and clinical efficacy of multiple doses (weeks 0, 3, 6 (240 mg/160 mg/160 mg; 80 mg/40 mg/40 mg; 160 mg/80 mg/80 mg and 560 mg/320 mg/320 mg)) of bimekizumab, a humanised monoclonal IgG1 antibody neutralising both IL-17A and IL-17F, were investigated. RESULTS: IL-17F induced qualitatively similar inflammatory responses to IL-17A in skin and joint cells. Neutralisation of IL-17A and IL-17F with bimekizumab more effectively suppressed in vitro cytokine responses and neutrophil chemotaxis than inhibition of IL-17A or IL-17F alone. The PoC trial met both prespecified efficacy success criteria and showed rapid, profound responses in both joint and skin (pooled top three doses vs placebo at week 8: American College of Rheumatology 20% response criteria 80.0% vs 16.7% (posterior probability >99%); Psoriasis Area and Severity Index 100% response criteria 86.7% vs 0%), sustained to week 20, without unexpected safety signals. CONCLUSIONS: These data support IL-17F as a key driver of human chronic tissue inflammation and the rationale for dual neutralisation of IL-17A and IL-17F in PsA and related conditions. TRIAL REGISTRATION NUMBER: NCT02141763; Results.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Glatt S, Baeten D, Baker T, et al. Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. Ann Rheum Dis. 2017. PMID: 29275332. doi:10.1136/annrheumdis-2017-212127

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。